Gilead acquires CymaBay for $4.3 billion

Gilead announced that it would acquire CymaBay, a company focused on developing treatments for metabolic and rare diseases with high unmet needs, for $4.3 billion. The acquisition will help Gilead refocus on liver disease, where the company is more skilled, and this transaction will be one of the key products that will help Gilead return to the TOP10 club.